Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival

A number of previous studies have reported that 30–50% of patients with colorectal cancer (CRC) harbor Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations, which is a major predictive biomarker of resistance to epidermal growth factor (EGFR)-targeted therapy. Treatment with an anti-EGFR inhi...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Mol Clin Oncol
Päätekijät: OSUMI, HIROKI, SHINOZAKI, EIJI, OSAKO, MASAHIKO, KAWAZOE, YOSHIMASA, OBA, MASARU, MISAKA, TAKAHARU, GOTO, TAKASHI, KAMO, HITOMI, SUENAGA, MITSUKUNI, KUMEKAWA, YOSUKE, OGURA, MARIKO, OZAKA, MASATO, MATSUSAKA, SATOSHI, CHIN, KEISHO, HATAKE, KIYOHIKO, MIZUNUMA, NOBUYUKI
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: D.A. Spandidos 2015
Aiheet:
Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4534836/
https://ncbi.nlm.nih.gov/pubmed/26623049
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2015.602
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia